Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The genetics and immunobiology of IgA nephropathy
Krzysztof Kiryluk, Jan Novak
Krzysztof Kiryluk, Jan Novak
Published June 2, 2014
Citation Information: J Clin Invest. 2014;124(6):2325-2332. https://doi.org/10.1172/JCI74475.
View: Text | PDF
Review Series

The genetics and immunobiology of IgA nephropathy

  • Text
  • PDF
Abstract

IgA nephropathy (IgAN) represents the leading cause of kidney failure among East Asian populations and the most frequent form of primary glomerulonephritis among Europeans. Patients with IgAN develop characteristic IgA1-containing immune complexes that deposit in the glomerular mesangium, producing progressive kidney injury. Recent studies define IgAN as an autoimmune trait of complex architecture with a strong genetic determination. This Review summarizes new insights into the role of the O-glycosylation pathway, anti-glycan immune response, mucosal immunity, antigen processing and presentation, and the alternative complement pathway in the pathogenesis of IgAN.

Authors

Krzysztof Kiryluk, Jan Novak

×

Figure 1

IgA1 structure and O-glycosylation pathway.

Options: View larger image (or click on image) Download as PowerPoint
IgA1 structure and O-glycosylation pathway.
(A) Structure of monomeric I...
(A) Structure of monomeric IgA1 and its hinge region in comparison with IgA2 (A2m(l) allotype) (36). The IgA1 hinge region consists of a short amino acid sequence between CH1 and CH2 of the α1 heavy chain. In contrast to IgA2, the IgA1 hinge region contains two octapeptide repeats composed of Ser, Thr, and proline (Pro) residues (arrows). Of the nine potential Ser and Thr O-glycosylation sites, three to six are usually occupied (numbered Ser/Thr residues) (25–29). (B) Biosynthesis of hinge-region O-glycans of human circulatory IgA1. The possible structures of O-glycans in the hinge region of IgA1 include GalNAc with galactose that may contain up to two N-acetylneuraminic acid residues. Galactose-deficient glycans include terminal or sialylated GalNAc. Enzymes catalyzing the specific steps in this pathway are shown.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts